{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:07:59Z","timestamp":1790827679675,"version":"4.1.0"},"reference-count":171,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cellular heterogeneity poses an immense therapeutic challenge in cancer due to a constant change in tumor cell characteristics, endowing cancer cells with the ability to dynamically shift between states. Intra-tumor heterogeneity is largely driven by cancer cell plasticity, demonstrated by the ability of malignant cells to acquire stemness and epithelial-to-mesenchymal transition (EMT) properties, to develop therapy resistance and to escape dormancy. These different aspects of cancer cell remodeling are driven by intrinsic as well as by extrinsic signals, the latter being dominated by factors of the tumor microenvironment. As part of the tumor milieu, chronic inflammation is generally regarded as a most influential player that supports tumor development and progression. In this review article, we put together recent findings on the roles of inflammatory elements in driving forward key processes of tumor cell plasticity. Using breast cancer as a representative research system, we demonstrate the critical roles played by inflammation-associated myeloid cells (mainly macrophages), pro-inflammatory cytokines [such as tumor necrosis factor \u03b1 (TNF\u03b1) and interleukin 6 (IL-6)] and inflammatory chemokines [primarily CXCL8 (interleukin 8, IL-8) and CXCL1 (GRO\u03b1)] in promoting tumor cell remodeling. These inflammatory components form a common thread that is involved in regulation of the three plasticity levels: stemness\/EMT, therapy resistance, and dormancy. In view of the fact that inflammatory elements are a common denominator shared by different aspects of tumor cell plasticity, it is possible that their targeting may have a critical clinical benefit for cancer patients.<\/jats:p>","DOI":"10.3389\/fonc.2020.614468","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T08:41:52Z","timestamp":1611650512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Inflammation-Driven Breast Tumor Cell Plasticity: Stemness\/EMT, Therapy Resistance and Dormancy"],"prefix":"10.3389","volume":"10","author":[{"given":"Tamir","family":"Baram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linor","family":"Rubinstein-Achiasaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagar","family":"Ben-Yaakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit","family":"Ben-Baruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00626","article-title":"Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance","volume":"9","author":"De Angelis","year":"2019","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101569","article-title":"Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities","volume":"11","author":"De Angelis","year":"2019","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semcancer.2018.08.009","article-title":"Cancer cell plasticity: Impact on tumor progression and therapy response","volume":"53","author":"da Silva-Diz","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.acr.2018.12.002","article-title":"Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting","volume":"141","author":"Talukdar","year":"2019","journal-title":"Adv Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00505","article-title":"Cellular Phenotype Plasticity in Cancer Dormancy and Metastasis","volume":"8","author":"Yang","year":"2018","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0068","article-title":"Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State","volume":"77","author":"Manjili","year":"2017","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.08.014","article-title":"Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer","volume":"17","author":"Brooks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00072","article-title":"Cellular Plasticity in Breast Cancer Progression and Therapy","volume":"7","author":"Kong","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ctrv.2011.11.005","article-title":"Molecular biology in breast cancer: intrinsic subtypes and signaling pathways","volume":"38","author":"Eroles","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e12532","article-title":"Pattern of metastatic spread and prognosis of breast cancer biologic subtypes","volume":"32","author":"Gerratana","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2686","article-title":"Chu D et al: Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms","volume":"78","author":"Paoletti","year":"2018","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2010.10.011","article-title":"Framework models of tumor dormancy from patient-derived observations","volume":"21","author":"Klein","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2020.04.017","article-title":"Cell plasticity in cancer: A complex interplay of genetic, epigenetic mechanisms and tumor micro-environment","volume":"34","author":"Shenoy","year":"2020","journal-title":"Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00498","article-title":"Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-018-0214-0","article-title":"Dormant tumour cells, their niches and the influence of immunity","volume":"20","author":"Goddard","year":"2018","journal-title":"Nat Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02335-7","article-title":"T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy","volume":"68","author":"Baxevanis","year":"2019","journal-title":"Cancer Immunol Immunother CII"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2019.06.021","article-title":"Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation","volume":"51","author":"Shalapour","year":"2019","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.ai.2015.12.002","article-title":"Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers","volume":"130","author":"Becht","year":"2016","journal-title":"Adv Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.156","article-title":"Implications of the tumor immune microenvironment for staging and therapeutics","volume":"31","author":"Taube","year":"2018","journal-title":"Mod Pathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00049","article-title":"Targeting Macrophages in Cancer: From Bench to Bedside","volume":"8","author":"Poh","year":"2018","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.08.010","article-title":"Tumor-associated macrophages in breast cancer: Innocent bystander or important player","volume":"70","author":"Qiu","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2011","article-title":"Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms","volume":"180","author":"Biswas","year":"2008","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082155","article-title":"Interleukin-1 Beta-A Friend or Foe in Malignancies","volume":"19","author":"Bent","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.142","article-title":"NF-kappaB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0309","article-title":"The role of IL-1B in breast cancer bone metastasis","volume":"25","author":"Tulotta","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12929-017-0398-9","article-title":"Preclinical and clinical aspects of TNF-alpha and its receptors TNFR1 and TNFR2 in breast cancer","volume":"24","author":"Martinez-Reza","year":"2017","journal-title":"J BioMed Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","article-title":"30 Years of NF-kappaB: A Blossoming of Relevance to Human Pathobiology","volume":"168","author":"Zhang","year":"2017","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02435-4","article-title":"Partners in crime: TNFalpha-based networks promoting cancer progression","volume":"69","author":"Ben-Baruch","year":"2020","journal-title":"Cancer Immunol Immunother CII"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122018","article-title":"What Is the Role of Interleukins in Breast Cancer Bone Metastases? A Systematic Review of Preclinical and Clinical Evidence","volume":"11","author":"Salamanna","year":"2019","journal-title":"Cancers"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting Interleukin-6 Signaling in Clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1042\/BST20180136","article-title":"The role of the interleukin (IL)-6\/IL-6 receptor axis in cancer","volume":"46","author":"Taher","year":"2018","journal-title":"Biochem Soc Trans"},{"key":"B44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cancers12020287","article-title":"Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers","volume":"12","author":"Do","year":"2020","journal-title":"Cancers"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.05.004","article-title":"Leukocyte trafficking in tumor microenvironment","volume":"35","author":"Del Prete","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","article-title":"Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases","volume":"1871","author":"Cheng","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy","volume":"10","author":"Mollica Poeta","year":"2019","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00952","article-title":"Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy","volume":"11","author":"Morein","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2013.10.006","article-title":"The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer","volume":"352","author":"Weitzenfeld","year":"2014","journal-title":"Cancer Lett"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.113.04er14a","article-title":"International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors","volume":"66","author":"Bachelerie","year":"2014","journal-title":"Pharmacol Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.272","article-title":"Inflammatory chemokines and metastasis-tracing the accessory","volume":"33","author":"Borsig","year":"2013","journal-title":"Oncogene"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03018","article-title":"Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer","volume":"9","author":"Eckert","year":"2018","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/path.3029","article-title":"The chemokine system and cancer","volume":"226","author":"Balkwill","year":"2012","journal-title":"J Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nri1964","article-title":"Tuning inflammation and immunity by chemokine sequestration: decoys and more","volume":"6","author":"Mantovani","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.05.014","article-title":"Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease","volume":"1843","author":"Turner","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cytogfr.2018.10.002","article-title":"Pro-inflammatory cytokines: The link between obesity and osteoarthritis","volume":"44","author":"Wang","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.65.3.291","article-title":"Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB","volume":"65","author":"Roebuck","year":"1999","journal-title":"J Leukoc Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066515","article-title":"Chemokine Expression in Inflamed Adipose Tissue Is Mainly Mediated by NF-kappaB","volume":"8","author":"Tourniaire","year":"2013","journal-title":"PloS One"},{"key":"B62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2407-11-130","article-title":"Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition","volume":"11","author":"Soria","year":"2011","journal-title":"BMC Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00757","article-title":"Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer","volume":"10","author":"Liubomirski","year":"2019","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-017-0600-4","article-title":"Intra-tumor heterogeneity from a cancer stem cell perspective","volume":"16","author":"Prasetyanti","year":"2017","journal-title":"Mol Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3336","article-title":"The epigenetics of epithelial-mesenchymal plasticity in cancer","volume":"19","author":"Tam","year":"2013","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00904","article-title":"Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies","volume":"11","author":"Tanabe","year":"2020","journal-title":"Front Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0067","article-title":"Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance","volume":"18","author":"Gooding","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.09.069","article-title":"Breast cancer stem cells, EMT and therapeutic targets","volume":"453","author":"Kotiyal","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081128","article-title":"CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs","volume":"11","author":"Sulaiman","year":"2019","journal-title":"Cancers"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1122-2","article-title":"EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness","volume":"69","author":"Sanchez-Tillo","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3041","article-title":"A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages","volume":"16","author":"Lu","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.03.032","article-title":"Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis","volume":"452","author":"Guo","year":"2019","journal-title":"Cancer Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2158","article-title":"Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network","volume":"79","author":"Valeta-Magara","year":"2019","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.03.016","article-title":"Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion","volume":"15","author":"Wu","year":"2009","journal-title":"Cancer Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41419-018-0876-3","article-title":"CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB\/SOX4 signaling","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3123","article-title":"Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1","volume":"72","author":"Li","year":"2012","journal-title":"Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/srep00539","article-title":"Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance","volume":"2","author":"Antoon","year":"2012","journal-title":"Sci Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22264","article-title":"TNFalpha up-regulates SLUG via the NF-kappaB\/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype","volume":"225","author":"Storci","year":"2010","journal-title":"J Cell Physiol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209808","article-title":"NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2","volume":"26","author":"Chua","year":"2007","journal-title":"Oncogene"},{"key":"B81","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-14-158","article-title":"The inflammatory cytokine TNFalpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells","volume":"14","author":"Leibovich-Rivkin","year":"2014","journal-title":"BMC Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/720536","article-title":"Progression of luminal breast tumors is promoted by menage a trois between the inflammatory cytokine TNFalpha and the hormonal and growth-supporting arms of the tumor microenvironment","volume":"2013","author":"Weitzenfeld","year":"2013","journal-title":"Mediators Inflammation"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1593\/neo.131688","article-title":"Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures","volume":"15","author":"Leibovich-Rivkin","year":"2013","journal-title":"Neoplasia"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4554","article-title":"TGFbeta\/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype","volume":"71","author":"Asiedu","year":"2011","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5680","article-title":"Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition","volume":"68","author":"Arima","year":"2008","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00804","article-title":"Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer","volume":"10","author":"Liubomirski","year":"2019","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00479","article-title":"Co-Inflammatory Roles of TGFbeta1 in the Presence of TNFalpha Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells","volume":"8","author":"Lerrer","year":"2017","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13213","article-title":"Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells","volume":"7","author":"Weitzenfeld","year":"2016","journal-title":"Oncotarget"},{"key":"B89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12964-017-0172-3","article-title":"Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence\/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line","volume":"15","author":"Ortiz-Montero","year":"2017","journal-title":"Cell Commun Signal"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.180","article-title":"Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells","volume":"28","author":"Sullivan","year":"2009","journal-title":"Oncogene"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1172\/JCI32533","article-title":"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland","volume":"117","author":"Sansone","year":"2007","journal-title":"J Clin Invest"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1018898108","article-title":"Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion","volume":"108","author":"Iliopoulos","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2013.01.007","article-title":"Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells","volume":"25","author":"Kim","year":"2013","journal-title":"Cell Signal"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44745","article-title":"The JAK2\/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors","volume":"121","author":"Marotta","year":"2011","journal-title":"J Clin Invest"},{"key":"B95","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421438111","article-title":"Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells","volume":"111","author":"Samanta","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2528","article-title":"Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6\/STAT3 and NO\/NOTCH Cross-talk Signaling","volume":"76","author":"Peng","year":"2016","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2741","article-title":"Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature","volume":"69","author":"Charafe-Jauffret","year":"2009","journal-title":"Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39397","article-title":"CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts","volume":"120","author":"Ginestier","year":"2010","journal-title":"J Clin Invest"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0156","article-title":"IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells","volume":"71","author":"Fernando","year":"2011","journal-title":"Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1056409","article-title":"Activation of IL-8 via PI3K\/Akt-dependent pathway is involved in leptin-mediated epithelial-mesenchymal transition in human breast cancer cells","volume":"16","author":"Wang","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1741-7007-10-73","article-title":"TWIST1 associates with NF-kappaB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production","volume":"10","author":"Li","year":"2012","journal-title":"BMC Biol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e2932","DOI":"10.1038\/cddis.2017.319","article-title":"An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells","volume":"8","author":"Jia","year":"2017","journal-title":"Cell Death Dis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/532161","article-title":"Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer","volume":"2014","author":"Chen","year":"2014","journal-title":"BioMed Res Int"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1063","article-title":"Targeting CXCR1\/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms","volume":"19","author":"Singh","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"14513","DOI":"10.1038\/s41598-017-15030-3","article-title":"Network-pharmacology-based validation of TAMS\/CXCL-1 as key mediator of XIAOPI formula preventing breast cancer development and metastasis","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"B107","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3892\/or.2017.5668","article-title":"GROalpha overexpression drives cell migration and invasion in triple negative breast cancer cells","volume":"38","author":"Bhat","year":"2017","journal-title":"Oncol Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1101\/gad.180331.111","article-title":"Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer","volume":"25","author":"Shree","year":"2011","journal-title":"Genes Dev"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3523","article-title":"Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts","volume":"66","author":"Paulus","year":"2006","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0221-4","article-title":"Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6898","article-title":"TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage","volume":"16","author":"Yang","year":"2017","journal-title":"Mol Med Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.01.022","article-title":"The depletion of interleukin-8 causes cell cycle arrest and increases the efficacy of docetaxel in breast cancer cells","volume":"431","author":"Shao","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aas8779","article-title":"Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance","volume":"12","author":"Goldman","year":"2019","journal-title":"Sci Signaling"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173107","article-title":"Targeting STAT3 in cancer and autoimmune diseases","volume":"878","author":"Gharibi","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B116","article-title":"Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells","volume":"61","author":"Conze","year":"2001","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4399","article-title":"Stat3\/Oct-4\/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066","volume":"53","author":"Cheng","year":"2018","journal-title":"Int J Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.07.088","article-title":"Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3\/MAPKs\/AKT signaling pathways","volume":"503","author":"Wang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","article-title":"JAK\/STAT3-Regulated Fatty Acid beta-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance","volume":"27","author":"Wang","year":"2018","journal-title":"Cell Metab"},{"key":"B120","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.canlet.2015.12.011","article-title":"Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells","volume":"372","author":"Sharma","year":"2016","journal-title":"Cancer Lett"},{"key":"B121","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1158\/1535-7163.MCT-12-0529","article-title":"Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis","volume":"12","author":"Sharma","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2017.09.030","article-title":"CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2","volume":"412","author":"Xu","year":"2018","journal-title":"Cancer Lett"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-013-9740-z","article-title":"Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients","volume":"20","author":"Xuan","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/cancers11020189","article-title":"Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells","volume":"11","author":"Castellaro","year":"2019","journal-title":"Cancers"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111932","article-title":"Inflammatory macrophage derived TNFalpha downregulates estrogen receptor alpha via FOXO3a inactivation in human breast cancer cells","volume":"390","author":"Gunnarsdottir","year":"2020","journal-title":"Exp Cell Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.158","article-title":"IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer","volume":"33","author":"Sun","year":"2014","journal-title":"Oncogene"},{"key":"B127","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/cas.14230","article-title":"Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K\/Akt\/mTOR in breast cancer","volume":"111","author":"Li","year":"2020","journal-title":"Cancer Sci"},{"key":"B128","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/1541-7786.MCR-12-0217","article-title":"STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells","volume":"11","author":"Yi","year":"2013","journal-title":"Mol Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0970","article-title":"TNFalpha-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer","volume":"23","author":"Mercogliano","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.4049\/jimmunol.1402603","article-title":"Intratumoral Delivery of IL-21 Overcomes Anti-Her2\/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype","volume":"194","author":"Xu","year":"2015","journal-title":"J Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.06.014","article-title":"Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population","volume":"47","author":"Korkaya","year":"2012","journal-title":"Mol Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90499","article-title":"Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer","volume":"127","author":"Taylor","year":"2017","journal-title":"J Clin Invest"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3468","article-title":"Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression","volume":"72","author":"Sisirak","year":"2012","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01680","article-title":"The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092626","article-title":"Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4110\/in.2020.20.e4","article-title":"Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy","volume":"20","author":"Kim","year":"2020","journal-title":"Immune Netw"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01633","article-title":"Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies","volume":"11","author":"Ngiow","year":"2020","journal-title":"Front Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834","article-title":"Foubert P et al: PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0395","article-title":"MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy","volume":"77","author":"Reinhardt","year":"2017","journal-title":"Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1737","article-title":"A Breakthrough: Macrophage-Directed Cancer Immunotherapy","volume":"76","author":"Mills","year":"2016","journal-title":"Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined Blockade of IL6 and PD-1\/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-020-0144-8","article-title":"PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transd Targ Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0608","article-title":"Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency","volume":"76","author":"De Cock","year":"2016","journal-title":"Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3603","article-title":"NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions","volume":"74","author":"Bowers","year":"2014","journal-title":"Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2008.00990.x","article-title":"Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer","volume":"116","author":"Retsky","year":"2008","journal-title":"APMIS"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3857-1","article-title":"The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases","volume":"158","author":"Dillekas","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.1.45","article-title":"Local recurrences following mastectomy: support for the concept of tumor dormancy","volume":"86","author":"Demicheli","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990250","article-title":"Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review","volume":"20","author":"Retsky","year":"2013","journal-title":"Curr Med Chem"},{"key":"B153","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2001-1326-1-17","article-title":"Promising development from translational or perhaps anti-translational research in breast cancer","volume":"1","author":"Retsky","year":"2012","journal-title":"Clin Transl Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2094-5","article-title":"NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup","volume":"134","author":"Retsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e3181d2ad07","article-title":"Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis","volume":"110","author":"Forget","year":"2010","journal-title":"Anesth Analg"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127282","article-title":"Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases","volume":"129","author":"Panigrahy","year":"2019","journal-title":"J Clin Invest"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3464","article-title":"The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy","volume":"10","author":"Krall","year":"2018","journal-title":"Sci Transl Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3587","article-title":"Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy","volume":"75","author":"Hughes","year":"2015","journal-title":"Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43653","article-title":"CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors","volume":"8","author":"Walens","year":"2019","journal-title":"Elife"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-015-9710-9","article-title":"Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment","volume":"32","author":"Sosnoski","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"B161","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12964-018-0259-5","article-title":"Reawakening of dormant estrogen-dependent human breast cancer cells by bone marrow stroma secretory senescence","volume":"16","author":"Tivari","year":"2018","journal-title":"Cell Commun Signal"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3408","article-title":"Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow","volume":"18","author":"Johnson","year":"2016","journal-title":"Nat Cell Biol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2940","article-title":"LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker","volume":"18","author":"Chen","year":"2012","journal-title":"Nat Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.414","article-title":"Inflammatory cytokine IL-8\/CXCL8 promotes tumour escape from hepatocyte-induced dormancy","volume":"118","author":"Khazali","year":"2018","journal-title":"Br J Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1038\/s41467-019-12108-6","article-title":"The CXCL5\/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis","volume":"10","author":"Romero-Moreno","year":"2019","journal-title":"Nat Commun"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i42.9300","article-title":"Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases","volume":"22","author":"Billmeier","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting Tumor-Associated Macrophages in Cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092818","article-title":"STAT3 in Breast Cancer Onset and Progression: A Matter of Time and Context","volume":"19","author":"Segatto","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.614468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T08:41:56Z","timestamp":1611650516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.614468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":171,"alternative-id":["10.3389\/fonc.2020.614468"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.614468","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"article-number":"614468"}}